These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 23730884)

  • 21. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis.
    Chang A; Tourtellotte WW; Rudick R; Trapp BD
    N Engl J Med; 2002 Jan; 346(3):165-73. PubMed ID: 11796850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inflammation stimulates remyelination in areas of chronic demyelination.
    Foote AK; Blakemore WF
    Brain; 2005 Mar; 128(Pt 3):528-39. PubMed ID: 15699059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Do central nervous system axons remyelinate?
    Nait-Oumesmar B; Lachapelle F; Decker L; Baron-Van Evercooren A
    Pathol Biol (Paris); 2000 Feb; 48(1):70-9. PubMed ID: 10729914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunization with a peptide of Semliki Forest virus promotes remyelination in experimental autoimmune encephalomyelitis.
    Mokhtarian F; Safavi F; Sarafraz-Yazdi E
    Brain Res; 2012 Dec; 1488():92-103. PubMed ID: 23031637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of remyelination in multiple sclerosis.
    Hanafy KA; Sloane JA
    FEBS Lett; 2011 Dec; 585(23):3821-8. PubMed ID: 21443876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple sclerosis - remyelination failure as a cause of disease progression.
    Hagemeier K; Brück W; Kuhlmann T
    Histol Histopathol; 2012 Mar; 27(3):277-87. PubMed ID: 22237705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myelin regeneration in demyelinating disorders: new developments in biology and clinical pathology.
    Zawadzka M; Franklin RJ
    Curr Opin Neurol; 2007 Jun; 20(3):294-8. PubMed ID: 17495623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endogenous leukemia inhibitory factor production limits autoimmune demyelination and oligodendrocyte loss.
    Butzkueven H; Emery B; Cipriani T; Marriott MP; Kilpatrick TJ
    Glia; 2006 May; 53(7):696-703. PubMed ID: 16498619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The remyelination Philosopher's Stone: stem and progenitor cell therapies for multiple sclerosis.
    Jadasz JJ; Aigner L; Rivera FJ; Küry P
    Cell Tissue Res; 2012 Jul; 349(1):331-47. PubMed ID: 22322424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haplotype matching is not an essential requirement to achieve remyelination of demyelinating CNS lesions.
    Tepavcević V; Blakemore WF
    Glia; 2006 Dec; 54(8):880-90. PubMed ID: 17006890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitory milieu at the multiple sclerosis lesion site and the challenges for remyelination.
    Galloway DA; Gowing E; Setayeshgar S; Kothary R
    Glia; 2020 May; 68(5):859-877. PubMed ID: 31441132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuropathology in multiple sclerosis: new concepts.
    Lassmann H
    Mult Scler; 1998 Jun; 4(3):93-8. PubMed ID: 9762654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting of IgMkappa antibodies to oligodendrocytes promotes CNS remyelination.
    Asakura K; Miller DJ; Pease LR; Rodriguez M
    J Neurosci; 1998 Oct; 18(19):7700-8. PubMed ID: 9742140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis.
    Warrington AE; Asakura K; Bieber AJ; Ciric B; Van Keulen V; Kaveri SV; Kyle RA; Pease LR; Rodriguez M
    Proc Natl Acad Sci U S A; 2000 Jun; 97(12):6820-5. PubMed ID: 10841576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting oligodendrocyte protection and remyelination in multiple sclerosis.
    Zhang J; Kramer EG; Mahase S; Dutta DJ; Bonnamain V; Argaw AT; John GR
    Mt Sinai J Med; 2011; 78(2):244-57. PubMed ID: 21425268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Studies of autoimmunity in multiple sclerosis.
    Whitaker JN; Snyder DS
    CRC Crit Rev Clin Neurobiol; 1984; 1(1):45-82. PubMed ID: 6400508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis.
    Dhib-Jalbut S
    Neurology; 2007 May; 68(22 Suppl 3):S13-21; discussion S43-54. PubMed ID: 17548563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cellular reaction to an acute demyelinating/remyelinating lesion of the rat brain stem: localisation of GD3 ganglioside immunoreactivity.
    Reynolds R; Wilkin GP
    J Neurosci Res; 1993 Nov; 36(4):405-22. PubMed ID: 8271315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent Advances on Immunosuppressive Drugs and Remyelination Enhancers for the Treatment of Multiple Sclerosis.
    Cadenas-Fernández J; Ahumada-Pascual P; Andreu LS; Velasco A
    Curr Pharm Des; 2021 Oct; 27(30):3273-3280. PubMed ID: 33504299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors that retard remyelination in multiple sclerosis with a focus on TIP30: a novel therapeutic target.
    Nakahara J; Aiso S; Suzuki N
    Expert Opin Ther Targets; 2009 Dec; 13(12):1375-86. PubMed ID: 19839715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.